The FDA has accepted Otsuka’s New Drug Application for centanafadine, a first-in-class norepinephrine, dopamine and serotonin reuptake inhibitor (NDSRI) for the treatment of attention-deficit ...

With an expiration date still more than a year away, here's what the latest details reveal.

Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor designed to address the core symptoms of ADHD in children and adults.

The FDA has started a priority review of Otsuka Pharma's triple-acting drug for attention-deficit hyperactivity disorder ...

An ADHD diagnosis means a person is prone to impulsivity and distractibility, which can manifest in the form of substance misuse, traffic accidents, criminality and even suicidal behavior. A recent ...

Treatment linked to reduced rates of first occurrence of suicidal behaviors, substance misuse, transport accidents, criminality. HealthDay News — Attention-deficit ...

Early drug treatment for ADHD in Sweden was tied to reduced risk of suicidal behavior, substance misuse, transport accidents, and crime. Benefits extended to recurrent events, possibly due to improved ...

The study included participants taking ADHD drug treatment (56.7%), and the researchers found this was associated with significantly reduced rates of suicidal behaviors, substance misuse, transport ...